<![CDATA[Perioperative Durvalumab Combo Boosts Survival in Resectable Gastric Cancer]]>
Phase 3positivedurvalumabFLOTPositive
AI Analysis
Summary
Final phase 3 MATTERHORN data demonstrate that perioperative durvalumab combined with FLOT chemotherapy significantly improves survival in patients with resectable gastric or gastroesophageal junction adenocarcinoma, positioning this combination as a new standard of care.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Final phase 3 MATTERHORN data shows perioperative durvalumab plus FLOT boosts survival in resectable gastric or gastroesophageal junction adenocarcinoma
Importance:8/10
Sentiment:
0.80
gastric cancergastroesophageal junction adenocarcinomaimmunotherapyphase 3perioperativesurvival benefit
Related Companies
Read the original article
Published by Cancer Network on September 12, 2026 2:00 PM